Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

This study is ongoing, but not recruiting participants.
Janssen Pharmaceuticals
Information provided by (Responsible Party):
ViiV Healthcare Identifier:
First received: April 17, 2014
Last updated: March 7, 2016
Last verified: March 2016
No Study Results Posted on for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2020
  Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: December 10, 2015